On Invalid Date, Redhill Biopharma (NASDAQ: RDHL) reported Q4 2022 earnings per share (EPS) of $0.00, up 100% year over year. Total Redhill Biopharma earnings for the quarter were -$3.73 million. In the same quarter last year, Redhill Biopharma's earnings per share (EPS) was -$20.00.
As of Q2 2023, Redhill Biopharma's earnings has grown year over year. Redhill Biopharma's earnings in the past year totalled -$71.67 million.
What is RDHL's earnings date?
Redhill Biopharma's earnings date is Invalid Date. Add RDHL to your watchlist to be reminded of RDHL's next earnings announcement.
What was RDHL's revenue last quarter?
On Invalid Date, Redhill Biopharma (NASDAQ: RDHL) reported Q4 2022 revenue of $12.80 million up 42.01% year over year. In the same quarter last year, Redhill Biopharma's revenue was $22.07 million.
What was RDHL's revenue growth in the past year?
As of Q2 2023, Redhill Biopharma's revenue has grown -27.94% year over year. This is 34.61 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 6.67%. Redhill Biopharma's revenue in the past year totalled $61.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.